At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLNO Soleno Therapeutics
Market Closed 03-06 16:00:00 EST
39.68
+1.11
+2.88%
盘后39.75
+0.07+0.18%
19:52 EST
High39.74Low37.50Vol1.76M
Open38.09D1 Closing38.57Amplitude5.81%
Mkt Cap2.05BTradable Cap1.78BTotal Shares51.62M
T/O68.71MT/O Rate3.91%Tradable Shares44.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Soleno Therapeutics Files Initial Beneficial Ownership Statement for CFO Jennifer Fulk
Reuters  ·  03-05 06:58
Soleno Therapeutics Files Initial Beneficial Ownership Statement for CFO Jennifer Fulk
Soleno Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-04
Soleno Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Soleno Therapeutics price target lowered to $100 from $120 at H.C. Wainwright
TIPRANKS  ·  03-04
Soleno Therapeutics price target lowered to $100 from $120 at H.C. Wainwright
Stock Track | Soleno Therapeutics Soars 5.43% in Post-Market Trading After Wells Fargo Maintains Overweight Rating
Stock Track  ·  02-28
Stock Track | Soleno Therapeutics Soars 5.43% in Post-Market Trading After Wells Fargo Maintains Overweight Rating
Soleno Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones  ·  02-28
Soleno Therapeutics Is Maintained at Overweight by Wells Fargo
Soleno Therapeutics price target lowered to $110 from $114 at Wells Fargo
TIPRANKS  ·  02-27
Soleno Therapeutics price target lowered to $110 from $114 at Wells Fargo
Soleno Therapeutics’ Risky Bet on VYKAT XR: Commercial, Regulatory, and Funding Hurdles Threaten Path to Profitability
TIPRANKS  ·  02-27
Soleno Therapeutics’ Risky Bet on VYKAT XR: Commercial, Regulatory, and Funding Hurdles Threaten Path to Profitability
Stock Track | Soleno Therapeutics Plummets 11.88% After TD Cowen Slashes Price Target
Stock Track  ·  02-26
Stock Track | Soleno Therapeutics Plummets 11.88% After TD Cowen Slashes Price Target
Stock Track | Soleno Therapeutics Plunges 8.32% in Pre-Market After TD Cowen Slashes Price Target
Stock Track  ·  02-26
Stock Track | Soleno Therapeutics Plunges 8.32% in Pre-Market After TD Cowen Slashes Price Target
Soleno Therapeutics Names Jennifer Fulk CFO as James Mackaness Retires
Reuters  ·  02-26
Soleno Therapeutics Names Jennifer Fulk CFO as James Mackaness Retires
Soleno Therapeutics Inc - on Feb 25, Co Appoints Jennifer Fulk as CFO Effective March 2, 2026 - SEC Filing
THOMSON REUTERS  ·  02-26
Soleno Therapeutics Inc - on Feb 25, Co Appoints Jennifer Fulk as CFO Effective March 2, 2026 - SEC Filing
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite
Reuters  ·  02-26
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite
Soleno Therapeutics: Strong Early Vykat XR Traction, Rapid Market Penetration, and Expanding Growth Opportunities Support Buy Rating
TIPRANKS  ·  02-26
Soleno Therapeutics: Strong Early Vykat XR Traction, Rapid Market Penetration, and Expanding Growth Opportunities Support Buy Rating
Soleno Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  02-26
Soleno Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Soleno Therapeutics reports Q4 EPS 80c vs. ($1.27) last year
TIPRANKS  ·  02-26
Soleno Therapeutics reports Q4 EPS 80c vs. ($1.27) last year
Soleno Therapeutics Q4 EPS $0.80 Beats $0.69 Estimate, Sales $91.730M Beat $88.548M Estimate
Benzinga  ·  02-26
Soleno Therapeutics Q4 EPS $0.80 Beats $0.69 Estimate, Sales $91.730M Beat $88.548M Estimate
Stock Track | Soleno Therapeutics Soars 6.26% Intraday on Strong Q4 Earnings
Stock Track  ·  02-26
Stock Track | Soleno Therapeutics Soars 6.26% Intraday on Strong Q4 Earnings
BRIEF-Soleno Therapeutics Q4 EPS USD 0.8
Reuters  ·  02-26
BRIEF-Soleno Therapeutics Q4 EPS USD 0.8
Soleno posts SLNO FY 2025 net income of USD 20.9 million as VYKAT XR FY product revenue hits USD 190.4 million
Reuters  ·  02-26
Soleno posts SLNO FY 2025 net income of USD 20.9 million as VYKAT XR FY product revenue hits USD 190.4 million
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
GlobeNewswire  ·  02-26
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

Introduction

Company Name.
Soleno Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Issue price:
--